Navigation Links
Resverlogix RVX-208 Second Clinical Trial Demonstrates Success on Key Reverse Cholesterol Transport Markers
Date:9/30/2009

    Powerful effects seen in all subjects including those with low HDL -
    representing a majority of myocardial infarct patients

    TSX Exchange Symbol: RVX

CALGARY, Sept. 29 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that results from the Company's Phase 1b/2a clinical trial have met and exceeded expectations by successfully concluding the drug, RVX-208, is safe and tolerable. Most importantly RVX-208 has met its primary endpoint to increase the production of plasma ApoA-I, the key cardioprotective protein in high-density lipoprotein (HDL), often referred to as "good" cholesterol. ApoA-I is generally endorsed as a key protective factor against atherosclerosis and cardiovascular disease with 40% of all first heart attack patients having low ApoA-I.

Resverlogix's Phase 1b/2a study tested RVX-208 for 28 days in three different dosing arms. The most pronounced results were demonstrated among those subjects with low HDL cholesterol levels. Low HDL is an important risk factor in coronary and cardiovascular disease patients. Resverlogix will continue to build upon its world leading position in development of novel small molecules that increase ApoA-l production and reverse cholesterol transport (RCT) markers in patients with high vascular risk profiles. RCT is a path by which cholesterol on the arterial wall is transported back to the liver by ApoA-I lipid complexes for excretion. Additional analysis was performed on other key RCT markers which achieved high levels of statistical significance. The Company has established a dosing range that it deems will be safe, well tolerated and effective for Phase 2 intravascular ultrasound (IVUS) development trials.

"The range of increase in ApoA-l production of all subjects, but in particular low HDL subjects over placebo demonstrated in this study is one of the most significant pieces of data for RVX-208. We have excee
'/>"/>

Resverlogix Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Resverlogix Phase 1b/2a Study Meets Primary Endpoint
2. Resverlogixs Success in Inflammation Program Results in 2 Patents Filed
3. Resverlogix Provides Quarterly Update
4. Resverlogix Board of Directors Update
5. Resverlogix Advances to Second Arm of Phase 1b/2a Clinical Trial
6. Resverlogix Announces Closing of Debt Redemption
7. Resverlogix Eliminates Sixty Percent of Remaining Debt
8. Resverlogix Issues a Management Statement
9. Resverlogix Board of Directors Update
10. Resverlogix Notice of Conference Call & Webcast
11. Jan Gray Joins Resverlogix Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 The Microcompetition with Foreign DNA ... disease. One of these latent viruses is the Epstein ... rheumatoid arthritis (RA). Rheumatoid arthritis (RA) is a chronic ... by the theory, a study found that RA patients ... (1). , What is Microcompetition? , Dr. Hanan ...
(Date:1/15/2014)... Sunnyvale, CA (PRWEB) January 15, 2014 ... of high throughput research solutions, today announced that ... companies, has received delivery of Freeslate’s CM ... form screening. , Lupin, headquartered in Mumbai, ... quality, affordable generic and branded formulations and Active ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Date: Friday, ... p.m. , Location: Warrington Country Club, 1360 Almshouse Road, ... Foundation, the only national nonprofit organization solely dedicated to ... quality of life for those affected worldwide, will host ... Warrington Country Club in Warrington, Pa. , Each ...
(Date:1/14/2014)... , Jan. 14, 2014  3D Communications, a leading provider ... major scientific, regulatory, business, and media events in ... , today announced its former associate Virginia Cox , ... office. Virginia Cox re-joins ... Commissioner for the Office of External Affairs at the U.S. ...
Breaking Biology Technology:Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Former FDA Associate Commissioner Returns To 3D Communications 2
... Recognized for Leadership in Clean Technology and Global ... 11 Solazyme, Inc., a,leading algal biotechnology company, ... as one of the GoingGreen 100 Top Private ... was compiled by the,AlwaysOn editorial panel. In order ...
... 11 ACCESS PHARMACEUTICALS, INC.,(OTC Bulletin Board: ... Marcial of BusinessWeek, highlighted Access Pharmaceuticals in ... The article is also available,on http://www.BusinessWeek.com ... The article focused upon the major ...
... 11 Archer Daniels,Midland Company (NYSE: ... Company,s,Commercial and Production group which is responsible ... John Rice, executive,vice president, Commercial and Production, ... business goals. I am confident that,these individuals ...
Cached Biology Technology:Solazyme, Inc. Selected by AlwaysOn as a GoingGreen 100 Top Private Company Award Winner 2Solazyme, Inc. Selected by AlwaysOn as a GoingGreen 100 Top Private Company Award Winner 3Access Highlighted in Recent BusinessWeek Article 2ADM Announces Appointments 2ADM Announces Appointments 3
(Date:4/15/2014)... Missouri researchers have previously shown that a genetic pre-disposition ... In a new study, Frank Booth, a professor in ... potential link between the genetic pre-disposition for high levels ... maturation occurs. , For his study, Booth selectively bred ... extreme laziness. Booth then put the rats in cages ...
(Date:4/15/2014)... dental researchers have found a less invasive way ... mouth to study how the mouth,s natural defenses ... some specialized immune cells (white blood cells known ... in the mouthor reject foreign tissues, such as ... about treating and preventing such health issues as ...
(Date:4/15/2014)... the world for which no pharmaceutical treatment exists. These ... mosquitoes in the tropics, as well as a type ... is easily spread by the hands and can be ... Researchers at Aalto University and the University of Eastern ... the spread of one type of virus into cells ...
Breaking Biology News(10 mins):Genetic pre-disposition toward exercise and mental development may be linked 2New method isolates immune cells for researchers to study how they ward off oral diseases 2Nanocrystalline cellulose modified into an efficient viral inhibitor 2
... MANHATTAN, Kan. -- Those choices at the pump may look ... University research team is conducting a study that could eventually ... early August, four faculty members from Kansas State University,s College ... from the U.S. departments of Agriculture and Energy under the ...
... (August 17, 2011) 23andMe, Inc., a leading personal ... a list of associations curated by the National Human ... demonstrating that self-reported medical data is effective and reliable ... in the journal PLoS ONE establish 23andMe,s ...
... University scientist studying human bone growth has received a ... to study a chemical compound with potential to fight ... professor of biomedical engineering at Indiana University-Purdue University Indianapolis ... at the IU School of Medicine, will investigate the ...
Cached Biology News:Harnessing the power of plants 2Harnessing the power of plants 323andMe replicates over 180 genetic associations with Web-based research platform 2New compound may accelerate bone healing, prevent osteoporosis 2New compound may accelerate bone healing, prevent osteoporosis 3
... coli containing a clone of the human Topoisomerase ... II alters the topological state of nucleic acids ... transient break which generates a separate DNA helix ... DNA passage mechanism, the enzyme can relax negatively ...
RNase-Free DNase 50 l...
supplied with 10x reaction buffer...
... RNase H degrades, as an endoribonuclease, ... DNA hybrids of natural origin, e.g. ... synthetic complexes, e.g. poly(A) x poly(dT). ... and 3-OH termini. Nearly no activity ...
Biology Products: